Helping transform lives through disruptive technology that improves thrombectomy

Fluid Biomed was founded by two neurosurgeons, Dr. John Wong and Dr. Alim Mitha, at the University of Calgary who have developed a polymer-based stent that can heal a blood vessel by diverting blood flow away from a weak brain aneurysm. Working together for the past two decades to help people with stroke, their drive and commitment to improve patient health sparked a vision to create a radical new stent to cure a wide variety of aneurysms with greater efficiency and safety.

Brain aneurysms afflict up to 5% of people and can lead to devastating stroke. Fluid Biomed is commercializing the first polymer-based brain stent to cure aneurysms. Their team of neurosurgeons, scientists, and engineers has designed the world’s first hybrid polymer-metal flow-diverting stent to cure this deadly disease. Uniquely constructed of dissolving polymer and metal, this innovative medical device provides a scaffold to allow better healing and visualization of blood vessels.

Their self-expanding stent is engineered to be highly flexible to navigate into delicate blood vessels of the brain. The unique use of polymer in their stent allows better healing of blood vessels while minimizing interference with radiological tests. As the company founders are academic specialists as well as practicing neurosurgeons, they are optimizing the medical device for patient safety, treatment efficacy, and physician ease-of-use.

Fluid Biomed has begun an international First-in-Human clinical trial to validate the technology. With the support of its partners, Fluid Biomed is achieving significant scientific, regulatory, and financing milestones along the pathway of product development. Fluid Biomed is well positioned to disrupt the stent market, and ultimately improve the quality of life and well-being of patients everywhere.